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test, Wilcoxon test, Chi-square test) were: number of patients exposed to allogeneic 
red cells, amount of blood transfusions, and the number of length of stay in hospital. 
An economic model was quantified the cost saving of EVICEL® in ICH. Results: 
preliminary results showed that application of EVICEL reduce number of transfused 
RBC, postoperative haemoglobin loss, and days of hospital stay. In the hospital cost. 
analysis EVICEL® predicts resource reduction with average cost-savings of € 1.227 
per patient. ConClusions: Overall, the results suggest that EVICEL are efficacious 
in reducing both post-operative blood loss, and hospital stay The protocol with 
EVICEL® produce clinical appropriateness and important cost savings for hospital.
PSY34
Economic Evaluation and addEd valuE for StakEholdErS of 
Switching from rituximab intravEnouS injEction to rituximab 
SubcutanEouS injEction in francE
Plommet N, Pau D, Tehard B
Roche SAS, Boulogne-Billancourt, France
objeCtives: A pilot project concerning the evaluation of potential cost-saving for 
switching from chemotherapy (rituximab) intravenous injection (IV) to chemother-
apy subcutaneous injection (SC) at national level in France” was selected to demon-
strate added benefits beyond clinical effectiveness. Methods: To define the added 
value of rituximab SC injection improvement a 5-step methodology was defined as 
follow: 1) Define the key value drivers (cost/benefits), 2) Implement decision tree, 
3) Estimate the associated patient flow, 4) Evaluate the direct and indirect costs of 
patient flow including hospital and insurance perspectives, 5) Communication to the 
stakeholders. For rituximab SC injection versus rituximab IV injection the decision 
tree model was developed using the French health care with rituximab marketing 
authorizations. Epidemiologic data were estimated with internal market share data 
and the French health watch institute. Results: Four main benefits emerged at 
national level; (i) A reduction in staff time was observed for nurses, pharmacists and 
technicians leading to a potential saving at 300 000€ per year. (ii) A potential saving 
of 500 000€ per year was observed for the reduction in consumables. (iii) The shorter 
occupancy of chair for SC injection was leaded to a potential saving of 700 000€ 
per year. (iv) Reduction in wastage was 300 000€ per year thanks to sub-cutaneous 
injection. ConClusions: Results showed that cost-saving from switching for IV 
to SC exist. Other potential benefits should be investigated to demonstrate all value 
of medicine product. Therefore, a quality of life study is planned to demonstrate 
potential added value of rituximab SC vs. rituximab IV in France. Cost-effectiveness 
study should be also performed to demonstrate potential cost saving per quality 
adjusted life year.
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objeCtives: Alpha-1 antitrypsin deficiency (AATD) is a rare, under-diagnosed disease 
that may predispose an individual to chronic obstructive pulmonary disease (COPD) 
early in life. Affected individuals often undergo long delays between symptomatology 
and diagnosis, and are commonly treated like standard COPD patients before receiv-
ing proper treatment with expensive AAT inhibitors. Recognizing the differences 
between these conditions may speed identification of AATD patients and prevent mis-
diagnosis. This study’s objective was to define differences between individuals with 
AATD and non-AATD associated COPD. Methods: Patient demographics, emergency 
room (ER) and inpatient visits, and costs (ER, inpatient, outpatient) between AATD and 
COPD patients were assessed using 2011-2013 Medicare data. ER and inpatient visits, 
and costs were assessed during a 1-year post period following confirmed COPD or 
AATD diagnosis. Results: Mean age of COPD (n= 183,832) and AATD (n= 279) cohorts 
were 72.6±11.3 and 64.6±11.7 years, respectively (p< 0.001). Among COPD patients, 
20.3% were receiving disability benefits, which was significantly less than AATD 
patients (40.1%; p< 0.001). COPD mean Charlson Comorbidity Index (CCI) score was 
3.7±2.7, while AATD was 2.4±2.0 (p< 0.001). AATD patients had more ER (58.4%) and 
inpatient (58.0%) visits than COPD patients (42.5% and 19.5%, respectively; p< 0.001). 
Despite the fact that only 13% of AATD patients were receiving AAT inhibitors, AATD 
total healthcare costs (per patient) were still $27,674 greater than COPD total costs 
(p< 0.001). ConClusions: Our results show that even though our AATD Medicare 
patients are younger and have lower CCI scores, they experience more ER and inpa-
tient visits, and cost more to the healthcare system compared to older, less healthy 
COPD patients. Identifying the medical burden of AATD, raises attention to the need 
for an effective screening tool for identifying AATD patients among those who have 
COPD as well as better understanding AATD disease progression.
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Economic imPact of EmPloYmEnt StatuS on thE Social coSt of 
morbid obESE PatiEntS SubmittEd to bariatric SurgErY
Bellelli S, Turchetti G
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objeCtives: The aim of the longitudinal multicenter study is to estimate the eco-
nomic impact of employment status on the social cost of a patient submitted to 
bariatric surgery techniques. Methods: Individual socio-economic and clinical 
data have been collected for adult patients in charge to 6 Hospital in Italy at time 
of intervention of gastric banding, gastric by-pass and sleeve gastrectomy and fol-
lowed up to 1 year. Direct medical costs were estimated using tariffs for laboratory 
tests, diagnostic exams, visits, and prices for drugs. Procedure and inpatient cost 
data were collected at Center level. Non medical costs included costs for travel and 
accommodation, domestic help and informal care. The human capital approach 
has been used for estimating the loss of productivity of patients. The incremen-
tal effects of employment status on social cost were estimated by multivariate 
scenario, with adoption of the most persistent biologic (ustekinumab), can lead to 
valuable savings through lower cost of maintenance phase, avoided re-inductions, 
and reduced visits.
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PharmacoEconomic analYSiS of uSing golimumab in thE carE of 
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objeCtives: Rare diseases such as ulcerative colitis (UC) have significant impact 
on patients and their families, as well as the healthcare systems and societies. 
The high costs of medicines makes actual researches in this field. The main aim 
of this study was to perform budget impact analysis of using combination of bio-
logics - infliximab + golimumab in equal proportions. Methods: Analysis of the 
published clinical trials was conducted to evaluate comparative efficacy and safety 
of the using of different types of biologics therapies – infliximab, golimumab. To 
measure costs of ulcerative colitis for the state budget were used “cost of illness” 
and “budget impact” analyses. Direct medical costs included diagnosis, treatments, 
medications, blood and its components, nutrient mixture and were calculated for 
1 year-therapy. In this study were performed 2 variants of UC treatment costs, in 
1st variant was used infliximab, in 2nd variant - infliximab + golimumab in equal 
proportions. Results: According to published trials golimumab was provided effi-
cacy similar to infliximab in inducing and maintaining clinical remission, clinical 
response, and mucosal healing. Loss of response was occurred in approximately 
30% of patients, leading to discontinuation of biologic therapy and/or colectomy. 
So using the combination of biologics was preferred. The mean annual overall 
direct health care cost of UC treatment for 1 patient with infliximab was esti-
mated to be 456 000 rubles ($ 8 514), and with infliximab + golimumab in equal 
proportions – 533 256 rubles ($9 957). Thus budget impact of using combination 
of 2 biologics - infliximab + golimumab in equal proportions was estimated to be 
14%. ConClusions: Golimumab was provided efficacy similar to infliximab and 
the use combination of 2 biologics infliximab + golimumab in equal proportions 
for treatment UC has little effect on the budget.
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objeCtives: to assess the cost effectiveness of the application of darbepoetin alfa 
vs other erythropoiesis-stimulating agents for anemia correction in patients on 
hemodialysis or peritoneal dialysis. Methods: The pharmacoeconomic model, 
providing the construction of decision tree, under which patients are treated by 
different ESP to achieve various levels of hemoglobin, was designed. To assess of 
the dosing schedule actual practice in the Russian healthcare system was perform 
a retrospective observational study (date from the 11 hospitals of Russia). The 
main method of pharmacoeconomic analysis was “cost-consequence” method 
and the analysis of the “impact on the budget”. A multivariant sensitivity analysis 
of the model relative to the cost of darbepoetin alfa ± 10 %, relative to the dose 
of darbepoetin alfa reduction at a level of 20 % and 47 % (based expert data) and 
relative to changes in hospitalization costs was performed. Results: The data 
on actual practice of darbepoetin alfa dossage in Russia indicate on a possible 
reduction of the dose during treatment an average of 47%. The total economy of 
budget per year (with respect to 1 patient) to hemodialysis patients may reach 
from 223,6 $ (for target hemoglobin values 11 (± 1) g/dL) to 616,47 $ (for hemo-
globin values 9 (± 1) g/dL). The total economy of budget per year for patients on 
peritoneal dialysis may reach from 216,32 $ (for 11 (± 1) g/dL) to 345,41 $ (for 
9 (± 1) g/dl). ConClusions: The darbepoetin alfa application for anemia cor-
rection in patients on hemodialysis or peritoneal dialysis is more cost-effective 
treatment option compared with other alternative erythropoiesis-stimulating 
drugs.
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EvicEl and bloodlESS Protocol in orthoPaEdicS SurgErY clinical 
EvidEncE and coSt- analYSiS : italian ExPEriEncE humanitaS 
rESEarch hoSPital
Scardino M, Martorelli F, Grappiolo G
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objeCtives: Blood transfusion and hemostasis are becoming an important aspect 
of preoperative planning and intraoperative decision making in orthopaedic sur-
gery. Total hip arthroplasty (THA), place patients at risk of significant blood loss, 
which can result in the need for transfusion, risk of postoperative anemia and 
infection, and increase hospital stay. Humanitas Hospital (ICH) use a new protocol 
“without blood” perioperative strategies include the use of autologous blood dona-
tion and administration of erythropoietin; intraoperative measures include acute 
normovolemic hemodilution, anesthesia, use of tranexamic acid, intraoperative 
and postoperative blood salvage, specialized cautery, and a new topical hemostatic 
agents (EVICEL). Evicel is a fibrin sealant (fibrinogen and high concentration of 
thrombin) hemostatic agent, facilitates hemostasis, reduce the volume of blood 
loss in postoperative. The potential role and cost saving generated from use of 
EVICEL in the “protocol without blood” to control blood loss, number of avoid blood 
transfusions and reduction of length of hospital stay in patients undergoing THA 
revisions. Methods: was evaluated in a retrospective observational controlled 
study in patients undergoing THA revision: one group was treated with EVICEL and a 
control group with the same protocol but without EVICEL. The outcomes measured (t 
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data source to identify patients with AS and their insurance claim records in 2013 
for in-patient care and out-patient care. The identified patients were stratified by 
AS-related medications for the comparisons on drug costs and non-drug medical 
costs. Generalized linear model (GLM) was conducted to assess the impact of the 
classified medications on on-drug medical costs after full adjustment of patient 
baseline characteristics including demography, AS-related to complications, and 
comorbidities. Results: Among the identified 1299 patients with diagnosed AS, the 
AS-related medications included nonsteroidal anti-inflammatory drugs (NSAIDs) 
(n= 234), immunosuppressant (n= 146), combination of NSAID and immunosuppres-
sant (n= 626), biologics (n= 60), and Chinese medications (n= 233). The total medical 
costs associated with AE-related treatments ranged from RMB 4,565 for Chinese 
medication to RMB 24,585 for biologics treatment (1 RMB = 0.16 US$). However, bio-
logics treatment and the combination treatment of NSAID and immunosuppressant 
had similar non-drug medical costs (RMB 7,039 versus RMB 7,450, p= 0.164). GLM 
regression analysis further confirmed highly comparable non-drug medical costs 
associated with biologics (coefficient: 0.0639, p = 0.741) relative to the combination 
treatment of NSAID and immunosuppressant. ConClusions: Among publically 
insured Chinese patients with AS, biologics treatments were associated with highly 
comparable non-drug medical costs as the combination treatment of NSAID and 
immunosuppressant. This finding suggests that biologics may effectively control 
health resource utilization through their superior treatment effects.
PSY40
coStS of abSEntEEiSm in PSoriatic and EntEroPathic arthroPathiES 
baSEd on rEal-lifE data from Poland’S Social inSurancE inStitution 
databaSE in 2013
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objeCtives: The aim of this study was to assess the indirect costs caused by absen-
teeism associated with psoriatic and enteropathic arthropathies from the perspective 
of the Social Insurance Institution (ZUS) in Poland. Methods: The estimates were 
based on data from the year 2013 concerning sick leave and the amount of short-
term disability, the sufferers of which claim rehabilitation benefit, and the amount of 
long-term disability (permanent or fixed time), the sufferers of which claim disability 
pension. Costs calculated taking into account Gross Domestic Product (GDP) per capita 
equaled € 10 278, Gross Value Added (GVA) per worker equaled € 24 680 and Gross 
Income (GI) per worker equaled € 7 339 were presented in 2013 prices. Results: Total 
indirect costs of psoriatic and enteropathic arthropathies in the year 2013 calculated 
using GDP per capita, GVA and GI per worker in Poland were € 7 341 217, € 17 628 441 
and € 5 242 346, respectively. The highest component of indirect costs was permanent 
long-term disability (43%). Fixed period long-term disability and short-term disability 
costs constitute 20% and 9% of total indirect costs, respectively. In 2013 Poland’s Social 
Insurance Institution database reported 2 100 patients that had 4 922 sick leave epi-
sodes, 180 short-term disability episodes and 80 long-term disability episodes. Indirect 
costs per patient associated with sick leave were € 1 030, € 2 474 and € 736 calculated 
using GDP, GVA and GI, respectively. Indirect costs per patient associated with short-
term disability were € 298, € 715 and € 212 respectively and associated with long-term 
disability were as high as € 2 168, € 5 206 and € 1 548, respectively. ConClusions: 
Psoriatic and enteropathic arthropathies in Poland generated high indirect costs. The 
main component was permanent long-term disability; short-term disability gener-
ated lower costs of lost productivity. The highest cost per patient was generated by 
permanent long-term disability.
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objeCtives: To estimate the direct cost of Del5q MDS from the perspective of 
the public healthcare system in Mexico Methods: We evaluated the amount of 
resources utilized by patients with Del5q MDS from an expert panel of eight hema-
tologist through the Delphi technique. Consensus was reached after two expert 
panel rounds and patterns of use were analyzed statistically. Unit costs of resources 
were extracted from institutional catalogues and annual cost estimations were 
performed for different health states. All values were expressed in US dollars of 
2015 Results: From the consensus of panel experts we found that management 
of patients with Del5q MDS at Mexican public healthcare institutions consisted 
of best supportive care with red blood cell (RBC) transfusions and erythropoiesis-
stimulating agents, and since these patients are RBC-transfusion dependent, they 
receive 33 units of RBC per year resulting in a cost of US$5,265.60. Iron overload is 
the main complication of transfusion dependency resulting in an annual cost of 
US$1,782.11 attributable to congestive heart failure. Other resources used to the 
treatment of the disease are drugs, labs, and visits that contribute to the total annual 
cost of US$30,647.78 per patient ConClusions: MDS patients with 5q deletion 
impose a high economic burden to the public healthcare system in Mexico, although 
the incidence is lower than other hematological malignancies
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Generalized Linear Models (log link, Gamma family) adjusting for gender, age, BMI, 
type of intervention, complications and comorbidites. Costs are expressed in Euro 
2013. Results: 280 patients (171 workers, 61%, and 109 no-workers including peo-
ple out of work, students, housewives and retirees, 39%) have been submitted to bar-
iatric surgery and followed up to 1 year after the intervention. The overall social cost, 
including costs of intervention and 1-year follow up, was € 11,310 (± € 3,778). Direct 
medical costs amounted to € 8,737 (± 2,527), representing the 77% of the overall cost, 
while direct non medical costs and indirect costs accounted for 13% and 10% (€ 1.497 
± € 1,928 and € 1,076 ± € 1,675). No working conditions had an incremental effect on 
direct non-medical costs of € 676 (95% CI: € 212-€ 1,140, p= 0.004). Working conditions 
increased indirect costs by € 1,384 (95% CI: € 1,002-€ 1,766, p= 0.000). ConClusions: 
Socio-economic determinant such as employment status of patient led to significant 
impacts on direct non medical costs and indirect costs of a patient submitted to 
bariatric surgery.
PSY37
thE indirEct coStS of inflammatorY bowEl diSEaSE (crohn’S diSEaSE 
and ulcErativE colitiS) aSSociatEd with abSEntEEiSm in Poland in 
2013
Kawalec P, Mocko P, Malinowski K
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objeCtives: The aim of this study was to assess the indirect costs caused by absen-
teeism associated with inflammatory bowel disease (IBD) - (Crohn’s disease – CD; 
and ulcerative colitis - UC) from the perspective of the Social Insurance Institution 
(ZUS) in Poland Methods: The estimates were based on data provided by ZUS 
referring to year 2013 and concerning absence from work due to the illness (sick 
leave), the amount of short-term disability, the sufferers of which claim rehabilita-
tion benefit, and the amount of permanent (or long-term) disability, the sufferers of 
which claim disability pension. Costs were calculated with Human Capital Approach 
methodology taking into account Gross Domestic Product (GDP) per capita equaled 
€ 10 278. Results: Total indirect costs of CD, UC in the year 2013 calculated using 
GDP per capita in Poland were € 7 817 156 and € 8 990 313, respectively. Total indirect 
costs of IBD in the year 2012 and 2013 in Poland were € 14 220 181 and € 16 807 469, 
respectively (an increase of nearly 15% because of substantial growth short-term 
disabilities). The highest component of indirect costs of IBD was sick leave (51%). 
Long and short-term disability costs constitute 39% (limited period – 19% and unlim-
ited period 20%) and 10% of total indirect costs of IBD, respectively. One sick leave of 
person with IBD generated the cost of lost productivity equal € 779 calculated using 
GDP per capita. Indirect cost of short-term disability for one entitlement to the ben-
efit of rehabilitation were € 7 314. Cost of one long-term benefit were much higher 
than short-term benefit and equaled for limited period € 36 714 and unlimited period 
€ 941. Total long-term disability costs amounted € 676 651. ConClusions: IBD in 
Poland generated high indirect costs. The main component was sick leave; reha-
bilitation benefit and disability pension generated lower costs of lost productivity.
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idioPathic PulmonarY fibroSiS: hoSPital diSEaSE managEmEnt and 
aSSociatEd coStS
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objeCtives: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibro-proliferative 
and fatal lung disease. A study was conducted to describe the causes and main 
comorbidities of hospitalized patients and associated costs in France. Methods: 
A retrospective, observational study was set up using the French hospital discharge 
database (PMSI). Patients with a first hospitalization for IPF (ICD-10 code: J841) in 
2008 were identified and followed during a 5-year period. As J841 code includes 
other fibrotic pulmonary diseases, an algorithm for data extraction was defined, 
with exclusion of age< 50 and presence of a differential diagnosis in the follow-
ing year (connective disease or pneumoconiosis). Patient characteristics, first stay 
and occurrence of events of special interest were described as well as associated 
costs. Results: In 2008, 6,476 patients newly hospitalized for IPF were identified, 
with a mean age of 75.4±10.3 years, and 56% were men. The mean total cost of 
hospitalizations per patient for the 5-year follow-up period was € 15,532±15,973. 
Main cost drivers were the serious events related to the disease, specifically acute 
exacerbation (37% of patients, with a 10% in-hospital mortality rate and a cost of 
€ 4,091±4,429/event), cardiac events (48% of patients with a 14% in-hospital mortality 
rate and a cost of € 5,731±5,463/event), acute respiratory infections (44% of patients 
with a 18% in-hospital mortality rate and a cost of € 7,471±7,981/event) and arterial 
thrombosis (12% of patients with a 20% in-hospital mortality rate and a cost of 
€ 7,467±7,216/event). Finally, 11% of patients received palliative care with a mean 
cost for the last year of life of € 14,807±11,979 per deceased patient. ConClusions: 
This study is the first providing extensive data on hospital management for patients 
with IPF in France, demonstrating high burden and hospital cost, especially for acute 
respiratory deteriorations. These results could be used in economic evaluations for 
IPF patients in France.
PSY39
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objeCtives: To estimate direct medical costs associated with ankylosing spondyli-
tis (AS) in publically insured Chinese patients. Methods: China Health Insurance 
Research Association (CHIRA) claim data containing patients randomly selected 
from publically insured urban residents and workers across China was used as the 
